Department of Internal Korean Medicine, College of Korean Medicine, Dae-Jeon University, Daejeon, Republic of Korea,Department. of Internal Korean Medicine, College of Korean Medicine, Se-Myung University, Chungcheongbukdo, South Korea.
Medicine (Baltimore). 2022 Mar 18;101(11). doi: 10.1097/MD.0000000000029087.
This systematic review and meta-analysis of randomized controlled trials (RCTs) will aim to assess the efficacy and safety of Yukmijihwang-hwan for type 2 diabetes without complications.
To identify eligible studies, we will perform a systematic search of the following electronic databases: MEDLINE (PubMed), EMBASE, the Cochrane Central Register of Controlled Trials, China National Knowledge Infrastructure, Citation Information by NII, Korean Information Service System, Korean Medical Database, Oriental Medicine Advanced Searching Integrated System, and ScienceON. Search terms will include "Type 2 Diabetes" for participants as well as "Yukmijihwang-tang" or "Liuwei dihuang tang" for interventions. Two independent researchers will perform data extraction and assessment using Cochrane's risk of bias tool, with disagreements being resolved through discussions with a third researcher.
This study will evaluate the antidiabetic effects of Yukmijihwang-hwan from 3 perspectives (blood glucose level, insulin resistance, and β-cell function) as well as its safety by reviewing the reported adverse effects.
This systematic review will provide evidence regarding the antidiabetic efficacy and safety of Yukmijihwang-tang in type 2 diabetes mellitus.
本系统评价和荟萃分析的随机对照试验（ RCT ）将旨在评估育阴降糖丸治疗 2 型糖尿病无并发症的疗效和安全性。
为了确定合格的研究，我们将进行系统检索以下电子数据库： MEDLINE （ PubMed ）， EMBASE ， Cochrane 中央对照试验注册库，中国国家知识基础设施，日本科学技术振兴机构引文数据库，韩国信息服务系统，韩国医学数据库，东方医学高级检索集成系统，以及科学在线。检索词将包括参与者的“ 2 型糖尿病”以及干预措施的“育阴降糖汤”或“六味地黄丸”。两名独立的研究人员将使用 Cochrane 的偏倚风险工具进行数据提取和评估，如果存在分歧，则通过与第三名研究人员进行讨论来解决。
本研究将从血糖水平、胰岛素抵抗和β细胞功能 3 个方面评估育阴降糖丸的降血糖作用，以及通过报告的不良反应评估其安全性。
本系统评价将为育阴降糖汤治疗 2 型糖尿病的降糖疗效和安全性提供证据。
